STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

JNJ JOHNSON & JOHNSON StockScouter® Report

6

StockScouter® Score

JOHNSON & JOHNSON, a large cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • One or more less experienced analysts has modestly increased quarterly earnings estimates for JNJ. Positive/Neutral
  • Short-term relative price momentum exhibits moderate strength. Postive/Neutral

 

Concerns

  • The enterprise value-to-sales ratio is higher than the average for comparably-sized companies in the StockScouter universe. Negative
  • The multi-period measure of relative price change and consistency is below average. Negative/Neutral

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that large cap stocks will be neutral, growth stocks will be in favor, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 20% done.
Progress: 60% done.
Low
High

Core Model Grades

B
C
D
D

Previous Ratings

7
7
8